Dr. Jeffrey Crawford
Claim this profileDuke University Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
21 reported clinical trials
57 drugs studied
About Jeffrey Crawford
Education:
- Obtained an MD from the University of North Carolina School of Medicine in 1978.
- Completed a Residency in Internal Medicine at Duke University Medical Center in 1981.
- Finished a Fellowship in Hematology/Oncology at Duke University Medical Center in 1983.
Experience:
- Currently a Professor of Medicine at Duke University School of Medicine.
- Serves as the Director of the Breast Cancer Program at the Duke Cancer Institute.
Area of expertise
1Lung Cancer
Stage III
Stage II
Stage I
2Non-Small Cell Lung Cancer
Stage III
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Jeffrey Crawford is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Jeffrey Crawford
Clinical Trial Related6 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jeffrey Crawford has experience with
- Pembrolizumab
- Carboplatin
- Autologous Hematopoietic Stem Cell Transplantation
- Rituximab
- Paclitaxel
- Pemetrexed Disodium
Breakdown of trials Jeffrey Crawford has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Crawford specialize in?
Jeffrey Crawford focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Jeffrey Crawford currently recruiting for clinical trials?
Yes, Jeffrey Crawford is currently recruiting for 4 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Crawford has studied deeply?
Yes, Jeffrey Crawford has studied treatments such as Pembrolizumab, Carboplatin, Autologous Hematopoietic Stem Cell Transplantation.
What is the best way to schedule an appointment with Jeffrey Crawford?
Apply for one of the trials that Jeffrey Crawford is conducting.
What is the office address of Jeffrey Crawford?
The office of Jeffrey Crawford is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.